Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Releases Earnings Results, Beats Estimates By $0.06 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) posted its quarterly earnings data on Wednesday. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.06, Zacks reports. The company had revenue of $649.61 million during the quarter, compared to analysts’ expectations of $644.68 million. Swedish Orphan Biovitrum had a return on equity of 11.93% and a net margin of 16.05%.

Swedish Orphan Biovitrum Stock Performance

Shares of OTCMKTS:BIOVF opened at $29.79 on Friday. The business’s 50-day moving average is $30.07 and its 200 day moving average is $29.33. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.04 and a quick ratio of 0.71. Swedish Orphan Biovitrum has a 1 year low of $24.08 and a 1 year high of $32.25. The firm has a market capitalization of $10.61 billion, a P/E ratio of 25.03 and a beta of 0.42.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.